Shanghai-based clinical-stage biopharmaceutical company Cytovant has raised $23.5 million in a new funding round, per an announcement on Friday. The round was led by global financial services company BNH Investment, a South Korean VC firm that focuses primarily on bio & healthcare industries.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
